6631 - 6640 of 8620 Results
Title
Year
- WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson’s Disease Monocytes2022OPENTitle: WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson’s Disease MonocytesJournal Name: Frontiers in Cellular NeurosciencePublisher: Frontiers Media SAVol: 16Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fncel.2022.892899Best OA location URL: https://www.frontiersin.org/articles/10.3389/fncel.2022.892899/pdfCitation Count: 21
-
OPENTitle: Editorial: Non-neuronal cell heterogeneity in the nervous system during health and diseaseJournal Name: Frontiers in Cellular NeurosciencePublisher: Frontiers Media SAVol: 16Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.3389/fncel.2022.1047296Best OA location URL: https://www.frontiersin.org/articles/10.3389/fncel.2022.1047296/pdfCitation Count: 1
- Current Status of Next-Generation Sequencing Approaches for Candidate Gene Discovery in Familial Parkinson´s Disease2022OPENTitle: Current Status of Next-Generation Sequencing Approaches for Candidate Gene Discovery in Familial Parkinson´s DiseaseJournal Name: Frontiers in GeneticsPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fgene.2022.781816Best OA location URL: https://www.frontiersin.org/articles/10.3389/fgene.2022.781816/pdfCitation Count: 9
- Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial2022OPENTitle: Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trialJournal Name: eBioMedicinePublisher: Elsevier BVVol: 80Issue #:Start Page: 104021End Page: 104021Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.ebiom.2022.104021Best OA location URL: http://www.thelancet.com/article/S2352396422002055/pdfCitation Count: 61
- The role of primary and secondary delays in the effective resonance frequency of acoustically interacting microbubbles2022OPENTitle: The role of primary and secondary delays in the effective resonance frequency of acoustically interacting microbubblesJournal Name: Ultrasonics SonochemistryPublisher: Elsevier BVVol: 86Issue #:Start Page: 106033End Page: 106033Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.ultsonch.2022.106033Best OA location URL: https://doi.org/10.1016/j.ultsonch.2022.106033Citation Count: 16
-
OPENTitle: Pathogenic LRRK2 regulates centrosome cohesion via Rab10/RILPL1-mediated CDK5RAP2 displacementJournal Name: iSciencePublisher: Elsevier BVVol: 25Issue #: 6Start Page: 104476End Page: 104476Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.isci.2022.104476Best OA location URL: http://www.cell.com/article/S2589004222007477/pdfCitation Count: 26
- Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age2022OPENTitle: Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing ageJournal Name: eBioMedicinePublisher: Elsevier BVVol: 82Issue #:Start Page: 104179End Page: 104179Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.ebiom.2022.104179Best OA location URL: http://www.thelancet.com/article/S2352396422003607/pdfCitation Count: 32
-
OPENTitle: Tailoring Motor Fluctuation Treatment: Beyond Levodopa Dose AdjustmentJournal Name: European Medical JournalPublisher: European Medical GroupVol:Issue #:Start Page: 20End Page: 27Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.33590/emj/10022165Best OA location URL: https://www.emjreviews.com/wp-content/uploads/2022/12/Tailoring-Motor-Fluctuation-Treatment-Beyond-Levodopa-Dose-Adjustment-1.pdfCitation Count: 0
-
OPENTitle: Botulinum Toxin in the Treatment of Cervical Dystonia: Evidence-Based ReviewJournal Name: DystoniaPublisher: Frontiers Media SAVol: 1Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/dyst.2022.10655Best OA location URL: https://www.frontierspartnerships.org/articles/10.3389/dyst.2022.10655/pdfCitation Count: 6
- Whole genome sequencing identifies candidate genes for familial essential tremor and reveals biological pathways implicated in essential tremor aetiology2022OPENTitle: Whole genome sequencing identifies candidate genes for familial essential tremor and reveals biological pathways implicated in essential tremor aetiologyJournal Name: eBioMedicinePublisher: Elsevier BVVol: 85Issue #:Start Page: 104290End Page: 104290Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.ebiom.2022.104290Best OA location URL: http://www.thelancet.com/article/S2352396422004728/pdfCitation Count: 22